#obesity-treatments

[ follow ]
#drug-pricing #glp-1 #wegovy #eli-lilly #weight-loss-drugs #pharma-valuation #medicare #glp-1-drugs #novo-nordisk
Medicine
fromwww.theguardian.com
3 months ago

Weight-loss race: how switch from injections to pills is expanding big pharma's hopes

Oral GLP-1 weight-loss pills like Wegovy are rapidly adopted, offering easier use but raising concerns about cost, supply and side-effects.
Medicine
fromwww.aljazeera.com
6 months ago

Eli Lilly becomes first pharma firm to join $1 trillion club

Eli Lilly reached $1 trillion market value as obesity drugs Mounjaro and Zepbound drove explosive sales and major stock gains.
fromFortune
6 months ago

Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune

President Donald Trump has announced a landmark deal aiming to expand Medicare coverage to include certain weight-loss medications, a move that could dramatically change access to these treatments for millions of older Americans. On November 6, Trump revealed that his administration had struck agreements with Eli Lilly and Novo Nordisk, the makers of popular weight-loss drugs including Ozempic and Wegovy, to reduce costs and allow for broader Medicare coverage starting in 2026.
US politics
Business
fromwww.theguardian.com
6 months ago

Ozempic maker Novo Nordisk cuts sales and profit forecasts again

Novo Nordisk cut sales and profit forecasts due to slowed profit growth and intensifying competition in the GLP-1 obesity and diabetes market.
Business
fromIrish Independent
8 months ago

Pfizer makes $4.9bn bet on obesity drugs

Pfizer will acquire obesity startup Metsera for about $4.9bn, paying $47.50 per share plus up to $22.50 in milestone-based payments.
[ Load more ]